Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229203 · ClinicalTrials.gov registry record · Phase 2
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
A Phase 2 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00229203 is a Phase 2 study that has completed, run by PharmaMar. The registered enrollment target is 51 participants.
The verdict
NCT00229203, a Phase 2 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a phase II study to determine the efficacy following treatment with Aplidin® 5 mg/m2, given as a 3 hours intravenous infusion every 2 weeks, in patients with relapsed or refractory multiple myeloma (MM).
Interventions
- DRUG Plitidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2005-02 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00229203
The ClinicalTrials.gov registry entry for NCT00229203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plitidepsin is the first listed.
NCT00229203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00229203 about?
NCT00229203 is a clinical study titled "A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma". This is a phase II study to determine the efficacy following treatment with Aplidin® 5 mg/m2, given as a 3 hours intravenous infusion every 2 weeks, in patients with relapsed or refractory multiple myeloma (MM).
What is the current status of trial NCT00229203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2005-02. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00229203?
The interventions under investigation include: Plitidepsin (DRUG).
Who is sponsoring clinical trial NCT00229203?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.